Skip to content
Showing 1 - 10 of 1467 results.
Go Medical, in collaboration with Columbia University and the New York State Psychiatric Institute, initiated the evaluation of the safety and pharmacokinetics of the OLANI for opioid use disorder.
Columbia Psychiatrists suggest that researchers, pharmaceutical companies, and the FDA reconsider placebo-controlled, relapse prevention studies in schizophrenia.
“It seems that there is some evidence that nitrates and their downstream products have profound effects on the same pathways that are implicated in bipolar disorder,” Writes Dr. Drew Ramsey.
“For my money, bowing is the way to go. Graceful, respectful, it communicates so much without the slightest physical contact,” writes Dr. Deborah Cabaniss after spending some time in Japan.
Dr. Christine Ann Denny’s laboratory is interested in the molecular mechanisms underlying learning and memory.
“I hate the fact that it’s so hard to access quality mental health care and there are so many things that can get in the way of being able to see someone like me,” says Dr. Ali Mattu.
Prescription medication may be enormously helpful, but "just taking a pill is usually not enough" to effectively cope with depression, says Dr. Diana Samuel.
A new study led by researchers at Columbia University suggests that vaping e-cigarettes may do more harm than good for young adults who also smoke.
Dr. Carl Hart talks about his work on the science of drug and cannabis addiction.
We spoke with David Hellerstein, MD, Director, Depression Evaluation Service, Columbia University Department of Psychiatry, about his Ganaxolone for postpartum depression study.